Androgen receptor signaling in prostate cancer

Cancer and Metastasis Reviews

Volumn 33, Issue 2-3, 2014, Pages 413-427

  Culig, Zoran ^a   Santer, Frédéric R ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Androgen receptor; Coactivator; Migration; miRNA; Mutation; Truncated receptor

Indexed keywords

ANDROGEN RECEPTOR; LIGAND; TRANSCRIPTION FACTOR;

ANIMAL; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; MUTATION; PATHOLOGY; PROSTATIC NEOPLASMS; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; MALE; MOLECULAR TARGETED THERAPY; MUTATION; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84905084724     PISSN: 01677659     EISSN: 15737233     Source Type: Journal    
DOI: 10.1007/s10555-013-9474-0     Document Type: Review

References (170)

1. van der Kwast, T. H., Schalken, J., Ruizeveld de Winter, J. A., van Vroonhoven, C. C., Mulder, E., Boersma, W., et al. (1991). Androgen receptors in endocrine-therapy-resistant human prostate cancer. International Journal of Cancer, 48, 189-193.
2. Hobisch, A., Culig, Z., Radmayr, C., Bartsch, G., Klocker, H., & Hittmair, A. (1995). Distant metastases from prostatic carcinoma express androgen receptor protein. Cancer Research, 55, 3068-3072.
3. Lu, S., Tsai, S. Y., & Tsai, M. J. (1997). Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Research, 57, 4511-4516. (Pubitemid 27441054)
4. Attardi, B. J., Burgenson, J., Hild, S. A., & Reel, J. R. (2004). Steroid hormonal regulation of growth, prostate specific antigen secretion, and transcription mediated by the mutated androgen receptor in CWR22Rv1 human prostate carcinoma cells. Molecular and Cellular Endocrinology, 222, 121-132. (Pubitemid 38906659)
5. Zhao, X. Y., Boyle, B., Krishnan, A. V., Navone, N. M., Peehl, D. M., & Feldman, D. (1999). Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. The Journal of Urology, 162, 2192-2199.
6. Denmeade, S. R., Sokoll, L. J., Dalrymple, S., Rosen, D. M., Gady, A. M., Bruzek, D., et al. (2003). Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models. The Prostate, 54, 249-257. (Pubitemid 36228161)
7. Heisler, L. E., Evangelou, A., Lew, A. M., Trachtenberg, J., Elsholtz, H. P., & Brown, T. J. (1997). Androgen-dependent cell cycle arrest and apoptotic death in PC-3 prostatic cell cultures expressing a full-length human androgen receptor. Molecular and Cellular Endocrinology, 126, 59-73. (Pubitemid 27055548)
8. Hsieh, T. C., & Wu, J. M. (1999). Differential effects on growth, cell cycle arrest, and induction of apoptosis by resveratrol in human prostate cancer cell lines. Experimental Cell Research, 249, 109-115.
9. Kyprianou, N., & Isaacs, J. T. (1989). Expression of transforming growth factor-beta in the rat ventral prostate during castration-induced programmed cell death. Molecular Endocrinology, 3, 1515-1522.
10. Brodin, G., ten Dijke, P., Funa, K., Heldin, C. H., & Landström, M. (1999). Increased smad expression and activation are associated with apoptosis in normal and malignant prostate after castration. Cancer Research, 59, 2731-2738. (Pubitemid 29269123)
11. Hayes, S. A., Zarnegar, M., Sharma, M., Yang, F., Peehl, D. M., ten Dijke, P., et al. (2001). SMAD3 represses androgen receptor-mediated transcription. Cancer Research, 61, 2112-2118. (Pubitemid 32692035)
12. Kyprianou, N., & Isaacs, J. T. (1988). Identification of a cellular receptor for transforming growth factor-beta in rat ventral prostate and its negative regulation by androgens. Endocrinology, 123, 2124-2131.
13. Eder, I. E., Culig, Z., Ramoner, R., Thurnher, M., Putz, T., Nessler-Menardi, C., et al. (2000). Inhibition of LncaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Therapy, 7, 997-1007. (Pubitemid 30483479)
14. Wang, L. G., Ossowski, L., & Ferrari, A. C. (2001). Overexpressed androgen receptor linked to p21WAF1 silencing may be responsible for androgen independence and resistance to apoptosis of a prostate cancer cell line. Cancer Research, 61, 7544-7551.
15. Lin, Y., Lu, Z., Kokontis, J., & Xiang, J. (2013). Androgen receptor primes prostate cancer cells to apoptosis through down-regulation of basal p21 expression. Biochemical and Biophysical Research Communications, 430, 289-293.
16. Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006). Mechanisms of cell death induced by histone deacetylase inhibitors in androgen receptor-positive prostate cancer cells. Molecular Cancer Research: MCR, 4, 113-123.
17. Zoubeidi, A., Zardan, A., Beraldi, E., Fazli, L., Sowery, R., Rennie, P., et al. (2007). Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Research, 67, 10455-10465. (Pubitemid 350070821)
18. Cornforth, A. N., Davis, J. S., Khanifar, E., Nastiuk, K. L., & Krolewski, J. J. (2008). FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells. Oncogene, 27, 4422-4433.
19. Lin, H.-K., Hu, Y.-C., Yang, L., Altuwaijri, S., Chen, Y.-T., Kang, H.-Y., et al. (2003). Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. The Journal of Biological Chemistry, 278, 50902-50907. (Pubitemid 38020321)
20. Wang, Y., Mikhailova, M., Bose, S., Pan, C.-X., deVere White, R. W., & Ghosh, P. M. (2008). Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene, 27, 7106-7117.
21. Ha, S., Ruoff, R., Kahoud, N., Franke, T. F., & Logan, S. K. (2011). Androgen receptor levels are upregulated by Akt in prostate cancer. Endocrine-Related Cancer, 18, 245-255.
22. Liao, X., Thrasher, J. B., Pelling, J., Holzbeierlein, J., Sang, Q.-X. A., & Li, B. (2003). Androgen stimulates matrix metalloproteinase-2 expression in human prostate cancer. Endocrinology, 144, 1656-1663. (Pubitemid 36543300)
23. Chuan, Y.-C., Pang, S.-T., Cedazo-Minguez, A., Norstedt, G., Pousette, A., & Flores-Morales, A. (2006). Androgen induction of prostate cancer cell invasion is mediated by ezrin. The Journal of Biological Chemistry, 281, 29938-29948. (Pubitemid 44537002)
24. Hara, T., Miyazaki, H., Lee, A., Tran, C. P., & Reiter, R. E. (2008). Androgen receptor and invasion in prostate cancer. Cancer Research, 68, 1128-1135. (Pubitemid 351272231)
25. Gohji, K., Fujimoto, N., Hara, I., Fujii, A., Gotoh, A., Okada, H., et al. (1998). Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension. International Journal of Cancer, 79, 96-101. (Pubitemid 28157734)
26. Castoria, G., D'Amato, L., Ciociola, A., Giovannelli, P., Giraldi, T., Sepe, L., et al. (2011). Androgen-induced cell migration: role of androgen receptor/filamin A association. PloS One, 6, e17218.
27. Gerhardt, J., Montani, M., Wild, P., Beer, M., Huber, F., Hermanns, T., et al. (2012). FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. The American Journal of Pathology, 180, 848-861.
28. Bonaccorsi, L., Carloni, V., Muratori, M., Salvadori, A., Giannini, A., Carini, M., et al. (2000). Androgen receptor expression in prostate carcinoma cells suppresses alpha6beta4 integrin-mediated invasive phenotype. Endocrinology, 141, 3172-3182. (Pubitemid 32269005)
29. Zhu, M.-L., Horbinski, C. M., Garzotto, M., Qian, D. Z., Beer, T. M., & Kyprianou, N. (2010). Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer. Cancer Research, 70, 7992-8002.
30. Sun, Y., Wang, B.-E., Leong, K. G., Yue, P., Li, L., Jhunjhunwala, S., et al. (2012). Androgen deprivation causes epithelial-mesenchymal transition in the prostate: implications for androgen-deprivation therapy. Cancer Research, 72, 527-536.
31. Krongrad, A., Wilson, C. M., Wilson, J. D., Allman, D. R., & McPhaul, M. J. (1991). Androgen increases androgen receptor protein while decreasing receptor mRNA in LNCaP cells. Molecular and Cellular Endocrinology, 76, 79-88.
32. Kokontis, J., Takakura, K., Hay, N., & Liao, S. (1994). Increased androgen receptor activity and altered c-myc expression in prostate cancer cells after long-termandrogen deprivation. Cancer Research, 54, 1566-1573. (Pubitemid 24106424)
33. Culig, Z., Hoffmann, J., Erdel, M., Eder, I. E., Hobisch, A., Hittmair, A., et al. (1999). Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. British Journal of Cancer, 81, 242-251. (Pubitemid 29423702)
34. Zegarra-Moro, O. L., Schmidt, L. J., Huang, H., & Tindall, D. J. (2002). Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research, 62, 1008-1013. (Pubitemid 34160279)
35. Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., et al. (1995). In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nature Genetics, 9, 401-406.
36. Mitchell, S. H., Zhu, W., & Young, C. Y. (1999). Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Research, 59, 5892-5895. (Pubitemid 30004946)
37. Zhu, W., Zhang, J. S., & Young, C. Y. (2001). Silymarin inhibits function of the androgen receptor by reducing nuclear localization of the receptor in the human prostate cancer cell line LNCaP. Carcinogenesis, 22, 1399-1403. (Pubitemid 32898696)
38. Neuwirt, H., Arias, M. C., Puhr, M., Hobisch, A., & Culig, Z. (2008). Oligomeric proanthocyanidin complexes (OPC) exert anti-proliferative and pro-apoptotic effects on prostate cancer cells. The Prostate, 68, 1647-1654.
39. Zhao, X. Y., Ly, L. H., Peehl, D. M., & Feldman, D. (1997). 1alpha, 25-dihydroxyvitamin D3 actions in LNCaP human prostate cancer cells are androgen-dependent. Endocrinology, 138, 3290-3298.
40. Sadar, M. D., & Gleave, M. E. (2000). Ligand-independent activation of the androgen receptor by the differentiation agent butyrate in human prostate cancer cells. Cancer Research, 60, 5825-5831.
41. Fang, Y.-X., & Gao, W.-Q. (2013). Roles of microRNAs during prostatic tumorigenesis and tumor progression. Oncogene. doi:10.1038/onc.2013.54.
42. Waltering, K. K., Porkka, K. P., Jalava, S. E., Urbanucci, A., Kohonen, P. J., Latonen, L. M., et al. (2011). Androgen regulation of micro-RNAs in prostate cancer. The Prostate, 71, 604-614.
43. Boll, K., Reiche, K., Kasack, K., Mörbt, N., Kretzschmar, A. K., Tomm, J. M., et al. (2013). miR-130a, miR-203 and miR-205 jointly repress key oncogenic pathways and are downregulated in prostate carcinoma. Oncogene, 32, 277-285.
44. Sun, T., Wang, Q., Balk, S., Brown, M., Lee, G.-S. M., & Kantoff, P. (2009). The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Research, 69, 3356-3363.
45. Spahn, M., Kneitz, S., Scholz, C.-J., Stenger, N., Rüdiger, T., Ströbel, P., et al. (2010). Expression of microRNA-221 is progressively reduced in aggressive prostate cancer and metastasis and predicts clinical recurrence. International Journal of Cancer, 127, 394-403.
46. Ribas, J., Ni, X., Haffner, M., Wentzel, E. A., Salmasi, A. H., Chowdhury, W. H., et al. (2009). miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth. Cancer Research, 69, 7165-7169.
47. Cao, P., Deng, Z., Wan, M., Huang, W., Cramer, S. D., Xu, J., et al. (2010). MicroRNA-101 negatively regulates Ezh2 and its expression is modulated by androgen receptor and HIF-1alpha/HIF-1beta. Molecular Cancer, 9, 108.
48. Östling, P., Leivonen, S.-K., Aakula, A., Kohonen, P., Mäkelä, R., Hagman, Z., et al. (2011). Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells. Cancer Research, 71, 1956-1967.
49. Rokhlin, O. W., Scheinker, V. S., Taghiyev, A. F., Bumcrot, D., Glover, R. A., & Cohen, M. B. (2008). MicroRNA-34 mediates AR-dependent p53-induced apoptosis in prostate cancer. Cancer Biology & Therapy, 7, 1288-1296.
50. Kashat,M., Azzouz, L., Sarkar, S. H., Kong, D., Li, Y., & Sarkar, F. H. (2012). Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness. American Journal of Translational Research, 4, 432-442.
51. Sikand, K., Slaibi, J. E., Singh, R., Slane, S. D., & Shukla, G. C. (2011). miR 488* inhibits androgen receptor expression in prostate carcinoma cells. International Journal of Cancer, 129, 810-819.
52. Lin, P.-C., Chiu, Y.-L., Banerjee, S., Park, K., Mosquera, J. M., Giannopoulou, E., et al. (2013). Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer Research, 73, 1232-1244.
53. Nadiminty, N., Tummala, R., Lou, W., Zhu, Y., Zhang, J., Chen, X., et al. (2012). MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. The Journal of Biological Chemistry, 287, 1527-1537.
54. Massard, C., & Fizazi, K. (2011). Targeting continued androgen receptor signaling in prostate cancer. Clinical Cancer Research, 17, 3876-3883.
55. Veldscholte, J., Berrevoets, C. A., Brinkmann, A. O., Grootegoed, J. A., & Mulder, E. (1992). Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry, 31, 2393-2399.
56. Sun, C., Shi, Y., Xu, L. L., Nageswararao, C., Davis, L. D., Segawa, T., et al. (2006). Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene, 25, 3905-3913. (Pubitemid 43990745)
57. Tepper, C. G., Boucher, D. L., Ryan, P. E., Ma, A.-H., Xia, L., Lee, L.-F., et al. (2002). Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research, 62, 6606-6614. (Pubitemid 35364127)
58. Culig, Z., Hobisch, A., Cronauer, M. V., Cato, A. C., Hittmair, A., Radmayr, C., et al. (1993). Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Molecular Endocrinology, 7, 1541-1550. (Pubitemid 24034236)
59. Tilley, W. D., Buchanan, G., Hickey, T. E., & Bentel, J. M. (1996). Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. Clinical Cancer Research, 2, 277-285. (Pubitemid 26074615)
60. Marcelli, M., Ittmann, M., Mariani, S., Sutherland, R., Nigam, R., Murthy, L., et al. (2000). Androgen receptor mutations in prostate cancer. Cancer Research, 60, 944-949. (Pubitemid 30129530)
61. Taplin, M. E., Bubley, G. J., Shuster, T. D., Frantz, M. E., Spooner, A. E., Ogata, G. K., et al. (1995). Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. The New England Journal of Medicine, 332, 1393-1398.
62. Taplin, M. E., Bubley, G. J., Ko, Y. J., Small, E. J., Upton, M., Rajeshkumar, B., et al. (1999). Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research, 59, 2511-2515. (Pubitemid 29269089)
63. Haapala, K., Hyytinen, E. R., Roiha, M., Laurila, M., Rantala, I., Helin, H. J., et al. (2001). Androgen receptor alterations in prostate cancer relapsed during a combined androgen blockade by orchiectomy and bicalutamide. Laboratory Investigation, 81, 1647-1651. (Pubitemid 33144427)
64. Hara, T., Miyazaki, J., Araki, H., Yamaoka, M., Kanzaki, N., Kusaka, M., et al. (2003). Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Research, 63, 149-153. (Pubitemid 36070433)
65. Yoshida, T., Kinoshita, H., Segawa, T., Nakamura, E., Inoue, T., Shimizu, Y., et al. (2005). Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient. Cancer Research, 65, 9611-9616. (Pubitemid 41541433)
66. Hyytinen, E.-R., Haapala, K., Thompson, J., Lappalainen, I., Roiha, M., Rantala, I., et al. (2002). Pattern of somatic androgen receptor gene mutations in patients with hormone-refractory prostate cancer. Laboratory Investigation, 82, 1591-1598. (Pubitemid 35332918)
67. Peng, Y., Li, C. X., Chen, F., Wang, Z., Ligr, M., Melamed, J., et al. (2008). Stimulation of prostate cancer cellular proliferation and invasion by the androgen receptor co-activator ARA70. The American Journal of Pathology, 172, 225-235. (Pubitemid 351186383)
68. Miyamoto, H., Yeh, S., Wilding, G., & Chang, C. (1998). Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 7379-7384. (Pubitemid 28293260)
69. Miyamoto, H., Yeh, S., Lardy, H., Messing, E., & Chang, C. (1998). Delta5-androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 95, 11083-11088. (Pubitemid 28450085)
70. Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., et al. (2007). Androgen deprivation increases p300 expression in prostate cancer cells. Cancer Research, 67, 3422-3430. (Pubitemid 46724883)
71. Comuzzi, B., Nemes, C., Schmidt, S., Jasarevic, Z., Lodde, M., Pycha, A., et al. (2004). The androgen receptor co-activator CBP is up-regulated following androgen withdrawal and is highly expressed in advanced prostate cancer. The Journal of Pathology, 204, 159-166. (Pubitemid 39335289)
72. Debes, J. D., Comuzzi, B., Schmidt, L. J., Dehm, S. M., Culig, Z., & Tindall, D. J. (2005). p300 regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Research, 65, 5965-5973.
73. Comuzzi, B., Lambrinidis, L., Rogatsch, H., Godoy-Tundidor, S., Knezevic, N., Krhen, I., et al. (2003). The transcriptional co-activator cAMP response element-binding protein-binding protein is expressed in prostate cancer and enhances androgen- and antiandrogen-induced androgen receptor function. The American Journal of Pathology, 162, 233-241. (Pubitemid 36042005)
74. Nishimura, K., Ting, H.-J., Harada, Y., Tokizane, T., Nonomura, N., Kang, H.-Y., et al. (2003). Modulation of androgen receptor transactivation by gelsolin: a newly identified androgen receptor coregulator. Cancer Research, 63, 4888-4894. (Pubitemid 37022622)
75. Wang, Y., Kreisberg, J. I., Bedolla, R. G., Mikhailova, M., deVere White, R. W., & Ghosh, P. M. (2007). A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene, 26, 6061-6070. (Pubitemid 47373811)
76. Santer, F. R., Höschele, P. P. S., Oh, S. J., Erb, H. H. H., Bouchal, J., Cavarretta, I. T., et al. (2011). Inhibition of the acetyltransferases p300 and CBP reveals a targetable function for p300 in the survival and invasion pathways of prostate cancer cell lines. Molecular Cancer Therapeutics, 10, 1644-1655.
77. Halkidou, K., Gnanapragasam, V. J., Mehta, P. B., Logan, I. R., Brady, M. E., Cook, S., et al. (2003). Expression of Tip60, an androgen receptor coactivator, and its role in prostate cancer development. Oncogene, 22, 2466-2477. (Pubitemid 36560730)
78. Shiota, M., Yokomizo, A., Masubuchi, D., Tada, Y., Inokuchi, J., Eto, M., et al. (2010). Tip60 promotes prostate cancer cell proliferation by translocation of androgen receptor into the nucleus. The Prostate, 70, 540-554.
79. Coffey, K., Blackburn, T. J., Cook, S., Golding, B. T., Griffin, R. J., Hardcastle, I. R., et al. (2012). Characterisation of a Tip60 specific inhibitor, NU9056, in prostate cancer. PloS One, 7, e45539.
80. Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., 3rd, Erdem, H., et al. (2006). Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Research, 66, 10594-10602. (Pubitemid 44799783)
81. Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., et al. (2004). Epidermal growth factor increases coactivation of the androgen receptor in recurrent prostate cancer. The Journal of Biological Chemistry, 279, 7119-7130. (Pubitemid 38248859)
82. Feng, S., Tang, Q., Sun, M., Chun, J. Y., Evans, C. P., & Gao, A. C. (2009). Interleukin-6 increases prostate cancer cells resistance to bicalutamide via TIF2. Molecular Cancer Therapeutics, 8, 665-671.
83. Froesch, B. A., Takayama, S., & Reed, J. C. (1998). BAG-1 L protein enhances androgen receptor function. The Journal of Biological Chemistry, 273, 11660-11666. (Pubitemid 28272067)
84. Agoulnik, I. U., Vaid, A., Bingman, W. E., 3rd, Erdeme, H., Frolov, A., Smith, C. L., et al. (2005). Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Research, 65, 7959-7967. (Pubitemid 41297275)
85. Ueda, T., Mawji, N. R., Bruchovsky, N., & Sadar, M. D. (2002). Ligand-independent activation of the androgen receptor by interleukin-6 and the role of steroid receptor coactivator-1 in prostate cancer cells. The Journal of Biological Chemistry, 277, 38087-38094. (Pubitemid 35157768)
86. Gnanapragasam, V. J., Leung, H. Y., Pulimood, A. S., Neal, D. E., & Robson, C. N. (2001). Expression of RAC 3, a steroid hormone receptor co-activator in prostate cancer. British Journal of Cancer, 85, 1928-1936. (Pubitemid 34775331)
87. Yan, J., Yu, C.-T., Ozen, M., Ittmann, M., Tsai, S. Y., & Tsai, M.-J. (2006). Steroid receptor coactivator-3 and activator protein-1 coordinately regulate the transcription of components of the insulin-like growth factor/AKT signaling pathway. Cancer Research, 66, 11039-11046. (Pubitemid 44877004)
88. Tien, J. C.-Y., Liu, Z., Liao, L., Wang, F., Xu, Y., Wu, Y.-L., et al. (2013). The Steroid Receptor Coactivator-3 Is Required for the Development of Castration-resistant Prostate Cancer. Cancer Research.
89. Kaulfuss, S., Grzmil, M., Hemmerlein, B., Thelen, P., Schweyer, S., Neesen, J., et al. (2008). Leupaxin, a novel coactivator of the androgen receptor, is expressed in prostate cancer and plays a role in adhesion and invasion of prostate carcinoma cells. Molecular Endocrinology, 22, 1606-1621. (Pubitemid 351920394)
90. Dong, Z., Liu, Y., Lu, S., Wang, A., Lee, K., Wang, L.-H., et al. (2006). Vav3 oncogene is overexpressed and regulates cell growth and androgen receptor activity in human prostate cancer. Molecular Endocrinology, 20, 2315-2325. (Pubitemid 44496404)
91. Liu, Y., Mo, J. Q., Hu, Q., Boivin, G., Levin, L., Lu, S., et al. (2008). Targeted overexpression of vav3 oncogene in prostatic epithelium induces nonbacterial prostatitis and prostate cancer. Cancer Research, 68, 6396-6406.
92. Clark, E. L., Coulson, A., Dalgliesh, C., Rajan, P., Nicol, S. M., Fleming, S., et al. (2008). The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer. Cancer Research, 68, 7938-7946.
93. Shiota, M., Bishop, J. L., Nip, K. M., Zardan, A., Takeuchi, A., Cordonnier, T., et al. (2013). Hsp27 regulates epithelial mesenchymal transition, metastasis, and circulating tumor cells in prostate cancer. Cancer Research, 73, 3109-3119.
94. Ni, L., Yang, C.-S., Gioeli, D., Frierson, H., Toft, D. O., & Paschal, B. M. (2010). FKBP51 promotes assembly of the Hsp90 chaperone complex and regulates androgen receptor signaling in prostate cancer cells. Molecular and Cellular Biology, 30, 1243-1253.
95. Taneja, S. S., Ha, S., Swenson, N. K., Torra, I. P., Rome, S., Walden, P. D., et al. (2004). ART-27, an androgen receptor coactivator regulated in prostate development and cancer. The Journal of Biological Chemistry, 279, 13944-13952. (Pubitemid 38468927)
96. Lapouge, G., Erdmann, E., Marcias, G., Jagla, M., Monge, A., Kessler, P., et al. (2007). Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation-a new paradigm for cooperation among prostate tumor cells. International Journal of Cancer, 121, 1238-1244. (Pubitemid 47293790)
97. Jagla, M., Fève, M., Kessler, P., Lapouge, G., Erdmann, E., Serra, S., et al. (2007). A splicing variant of the androgen receptor detected in a metastatic prostate cancer exhibits exclusively cytoplasmic actions. Endocrinology, 148, 4334-4343.
98. Dehm, S. M., & Tindall, D. J. (2011). Alternatively spliced androgen receptor variants. Endocrine-Related Cancer, 18, R183-196.
99. Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., et al. (2009). A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research, 69, 2305-2313.
100. Mediwala, S. N., Sun, H., Szafran, A. T., Hartig, S. M., Sonpavde, G., Hayes, T. G., et al. (2013). The activity of the androgen receptor variant AR-V7 is regulated by FOXO1 in a PTEN-PI3K-AKT-dependent way. The Prostate, 73, 267-277.
101. Watson, P. A., Chen, Y. F., Balbas, M. D., Wongvipat, J., Socci, N. D., Viale, A., et al. (2010). Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proceedings of the National Academy of Sciences of the United States of America, 107, 16759-16765.
102. Hu, R., Lu, C., Mostaghel, E. A., Yegnasubramanian, S., Gurel, M., Tannahill, C., et al. (2012). Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Research, 72, 3457-3462.
103. Li, Y., Chan, S. C., Brand, L. J., Hwang, T. H., Silverstein, K. A. T., & Dehm, S. M. (2013). Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Research, 73, 483-489.
104. Mostaghel, E. A., Marck, B. T., Plymate, S. R.,Vessella, R. L., Balk, S., Matsumoto, A. M., et al. (2011). Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clinical Cancer Research, 17, 5913-5925.
105. Hörnberg, E., Ylitalo, E. B., Crnalic, S., Antti, H., Stattin, P., Widmark, A., et al. (2011). Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival. PloS One, 6, e19059.
106. Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., et al. (1994). Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Research, 54, 5474-5478.
107. Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010). Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases. Oncogene, 29, 3208-3216.
108. Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999). A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nature Medicine, 5, 280-285. (Pubitemid 29124362)
109. Nazareth, L. V., & Weigel, N. L. (1996). Activation of the human androgen receptor through a protein kinase A signaling pathway. The Journal of Biological Chemistry, 271, 19900-19907.
110. Wang, G., Jones, S. J. M., Marra, M. A., & Sadar, M. D. (2006). Identification of genes targeted by the androgen and PKA signaling pathways in prostate cancer cells. Oncogene, 25, 7311-7323. (Pubitemid 44809097)
111. Yuan, T.-C., Veeramani, S., & Lin, M.-F. (2007). Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocrine-Related Cancer, 14, 531-547. (Pubitemid 350074046)
112. Desai, S. J., Ma, A.-H., Tepper, C. G., Chen, H.-W., & Kung, H.-J. (2006). Inappropriate activation of the androgen receptor by nonsteroids: involvement of the Src kinase pathway and its therapeutic implications. Cancer Research, 66, 10449-10459. (Pubitemid 44799766)
113. Giri, D., Ozen, M., & Ittmann, M. (2001). Interleukin-6 is an autocrine growth factor in human prostate cancer. The American Journal of Pathology, 159, 2159-2165. (Pubitemid 33104270)
114. Culig, Z., Steiner, H., Bartsch, G., & Hobisch, A. (2005). Interleukin-6 regulation of prostate cancer cell growth. Journal of Cellular Biochemistry, 95, 497-505. (Pubitemid 41420180)
115. Jin, R. J., Lho, Y., Connelly, L., Wang, Y., Yu, X., Saint Jean, L., et al. (2008). The nuclear factor-kappaB pathway controls the progression of prostate cancer to androgen-independent growth. Cancer Research, 68, 6762-6769.
116. Ueda, T., Bruchovsky, N., & Sadar, M. D. (2002). Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways. The Journal of Biological Chemistry, 277, 7076-7085. (Pubitemid 34959964)
117. Guo, Z., Dai, B., Jiang, T., Xu, K., Xie, Y., Kim, O., et al. (2006). Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 10, 309-319. (Pubitemid 44512189)
118. Asim, M., Siddiqui, I. A., Hafeez, B. B., Baniahmad, A., & Mukhtar, H. (2008). Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene, 27, 3596-3604. (Pubitemid 351793796)
119. Twillie, D. A., Eisenberger, M. A., Carducci, M. A., Hseih, W. S., Kim, W. Y., & Simons, J. W. (1995). Interleukin-6: a candidate mediator of human prostate cancer morbidity. Urology, 45, 542-549.
120. Hobisch, A., Rogatsch, H., Hittmair, A., Fuchs, D., Bartsch, G., Jr., Klocker, H., et al. (2000). Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. The Journal of Pathology, 191, 239-244. (Pubitemid 30441246)
121. Santer, F. R., Malinowska, K., Culig, Z., & Cavarretta, I. T. (2010). Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells. Endocrine-Related Cancer, 17, 241-253.
122. Spiotto, M. T., & Chung, T. D. (2000). STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. The Prostate, 42, 186-195.
123. Malinowska, K., Neuwirt, H., Cavarretta, I. T., Bektic, J., Steiner, H., Dietrich, H., et al. (2009). Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor. Endocrine-Related Cancer, 16, 155-169.
124. Gross, M., Liu, B., Tan, J., French, F. S., Carey, M., & Shuai, K. (2001). Distinct effects of PIAS proteins on androgen-mediated gene activation in prostate cancer cells. Oncogene, 20, 3880-3887. (Pubitemid 32646198)
125. Hoefer, J., Schäfer, G., Klocker, H., Erb, H. H. H., Mills, I. G., Hengst, L., et al. (2012). PIAS1 is increased in human prostate cancer and enhances proliferation through inhibition of p21. The American Journal of Pathology, 180, 2097-2107.
126. Chun, J. Y., Nadiminty, N., Dutt, S., Lou, W., Yang, J. C., Kung, H.-J., et al. (2009). Interleukin-6 regulates androgen synthesis in prostate cancer cells. Clinical Cancer Research, 15, 4815-4822.
127. Smith, P. C., & Keller, E. T. (2001). Anti-interleukin-6 monoclonal antibody induces regression of human prostate cancer xenografts in nude mice. The Prostate, 48, 47-53.
128. Wallner, L., Dai, J., Escara-Wilke, J., Zhang, J., Yao, Z., Lu,Y., et al. (2006). Inhibition of interleukin-6 with CNTO328, an anti-interleukin-6 monoclonal antibody, inhibits conversion of androgen-dependent prostate cancer to an androgen-independent phenotype in orchiectomized mice. Cancer Research, 66, 3087-3095.
129. Karkera, J., Steiner, H., Li, W., Skradski, V., Moser, P. L., Riethdorf, S., et al. (2011). The anti-interleukin-6 antibody siltuximab down-regulates genes implicated in tumorigenesis in prostate cancer patients from a phase I study. The Prostate, 71, 1455-1465.
130. Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., et al. (2004). Phosphorylation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Research, 64, 5232-5236. (Pubitemid 39006542)
131. Bakin, R. E., Gioeli, D., Sikes, R. A., Bissonette, E. A., & Weber, M. J. (2003). Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Research, 63, 1981-1989. (Pubitemid 36460867)
132. Shu, S.-K., Liu, Q., Coppola, D., & Cheng, J. Q. (2010). Phosphorylation and activation of androgen receptor by Aurora-A. The Journal of Biological Chemistry, 285, 33045-33053.
133. Mahajan, K., Challa, S., Coppola, D., Lawrence, H., Luo, Y., Gevariya, H., et al. (2010). Effect of Ack1 tyrosine kinase inhibitor on ligand-independent androgen receptor activity. The Prostate, 70, 1274-1285.
134. Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., et al. (2008). Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis, 29, 1148-1156. (Pubitemid 351958693)
135. Lee, S. O., Lou, W., Hou, M., Onate, S. A., & Gao, A. C. (2003). Interleukin-4 enhances prostate-specific antigen expression by activation of the androgen receptor and Akt pathway. Oncogene, 22, 7981-7988. (Pubitemid 37175863)
136. Korenman, S. G., & Lipsett, M. B. (1965). Direct peripheral conversion of dehydroepiandrosterone to testosterone glucuronoside. Steroids, 5, 509-517.
137. Locke, J. A., Guns, E. S., Lubik, A. A., Adomat, H. H., Hendy, S. C., Wood, C. A., et al. (2008). Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research, 68, 6407-6415.
138. Barrie, S. E., Potter, G. A., Goddard, P. M., Haynes, B. P., Dowsett, M., & Jarman, M. (1994). Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). The Journal of Steroid Biochemistry and Molecular Biology, 50, 267-273. (Pubitemid 24309119)
139. Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., et al. (2008). Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. Journal of Clinical Oncology, 26, 4563-4571.
140. Danila, D. C., Morris, M. J., de Bono, J. S., Ryan, C. J., Denmeade, S. R., Smith, M. R., et al. (2010). Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. Journal of Clinical Oncology, 28, 1496-1501.
141. Fizazi, K., Scher, H. I., Molina, A., Logothetis, C. J., Chi, K. N., Jones, R. J., et al. (2012). Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology, 13, 983-992.
142. Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., et al. (2013). Abiraterone in metastatic prostate cancer without previous chemotherapy. The New England Journal of Medicine, 368, 138-148.
143. Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., et al. (2011). Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is up-regulated by treatment with CYP17A1 inhibitors. Cancer Research, 71, 6503-6513.
144. Veldscholte, J., Ris-Stalpers, C., Kuiper, G. G., Jenster, G., Berrevoets, C., Claassen, E., et al. (1990). A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to antiandrogens. Biochemical and Biophysical Research Communications, 173, 534-540.
145. Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., et al. (2009). Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science, 324, 787-790.
146. Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., et al. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. The New England Journal of Medicine, 367, 1187-1197.
147. Scher, H. I., Beer, T. M., Higano, C. S., Anand, A., Taplin, M.-E., Efstathiou, E., et al. (2010). Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet, 375, 1437-1446.
148. Loriot, Y., Bianchini, D., Ileana, E., Sandhu, S., Patrikidou, A., Pezaro, C., et al. (2013). Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Annals of Oncology.
149. Handratta, V. D., Vasaitis, T. S., Njar, V. C. O., Gediya, L. K., Kataria, R., Chopra, P., et al. (2005). Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of Medicinal Chemistry, 48, 2972-2984. (Pubitemid 40552912)
150. Vasaitis, T., Belosay, A., Schayowitz, A., Khandelwal, A., Chopra, P., Gediya, L. K., et al. (2008). Androgen receptor inactivation contributes to antitumor efficacy of 17{alpha}-hydroxylase/17,20-lyase inhibitor 3beta-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene in prostate cancer. Molecular Cancer Therapeutics, 7, 2348-2357.
151. Clegg, N. J., Wongvipat, J., Joseph, J. D., Tran, C., Ouk, S., Dilhas, A., et al. (2012). ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Research, 72, 1494-1503.
152. Attar, R. M., Jure-Kunkel, M., Balog, A., Cvijic, M. E., Dell-John, J., Rizzo, C. A., et al. (2009). Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer. Cancer Research, 69, 6522-6530.
153. Rathkopf, D., Liu, G., Carducci, M. A., Eisenberger, M. A., Anand, A., Morris, M. J., et al. (2011). Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clinical Cancer Research, 17, 880-887.
154. Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., et al. (2011). Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorganic & Medicinal Chemistry, 19, 6383-6399.
155. Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., et al. (2012). Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys. The Journal of Steroid Biochemistry and Molecular Biology, 129, 115-128.
156. Hara, T., Kouno, J., Kaku, T., Takeuchi, T., Kusaka, M., Tasaka, A., et al. (2013). Effect of a novel 17,20-lyase inhibitor, orteronel (TAK-700), on androgen synthesis in male rats. The Journal of Steroid Biochemistry and Molecular Biology, 134, 80-91.
157. Andersen, R. J., Mawji, N. R., Wang, J., Wang, G., Haile, S., Myung, J.-K., et al. (2010). Regression of castrate-recurrent prostate cancer by a small-molecule inhibitor of the amino-terminus domain of the androgen receptor. Cancer Cell, 17, 535-546.
158. Jenster, G., van der Korput, H. A. G. M., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., & Brinkmann, A. O. (1991). Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Molecular Endocrinology, 5, 1396-1404.
159. Fang, Y., Fliss, A. E., Robins, D. M., & Caplan, A. J. (1996). Hsp90 regulates androgen receptor hormone binding affinity in vivo. The Journal of Biological Chemistry, 271, 28697-28702. (Pubitemid 26374699)
160. Vanaja, D. K., Mitchell, S. H., Toft, D. O., & Young, C. Y. F. (2002). Effect of geldanamycin on androgen receptor function and stability. Cell Stress & Chaperones, 7, 55-64. (Pubitemid 36138904)
161. Heath, E. I., Hillman, D. W., Vaishampayan, U., Sheng, S., Sarkar, F., Harper, F., et al. (2008). A phase II trial of 17-allylamino-17- demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clinical Cancer Research, 14, 7940-7946.
162. Oh, W. K., Galsky, M. D., Stadler, W. M., Srinivas, S., Chu, F., Bubley, G., et al. (2011). Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (ipi-504), in patients with castration-resistant prostate cancer. Urology, 78, 626-630.
163. Shafi, A. A., Cox, M. B., & Weigel, N. L. (2013). Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids, 78, 548-554.
164. He, S., Zhang, C., Shafi, A. A., Sequeira, M., Acquaviva, J., Friedland, J. C., et al. (2013). Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. International Journal of Oncology, 42, 35-43.
165. Chou, Y.-W., Chaturvedi, N. K., Ouyang, S., Lin, F.-F., Kaushik, D., Wang, J., et al. (2011). Histone deacetylase inhibitor valproic acid suppresses the growth and increases the androgen responsiveness of prostate cancer cells. Cancer Letters, 311, 177-186.
166. Gravina, G. L., Marampon, F., Muzi, P., Mancini, A., Piccolella, M., Negri-Cesi, P., et al. (2013). PXD101 potentiates hormonal therapy and prevents the onset of castration-resistant phenotype modulating androgen receptor, HSP90, and CRM1 in preclinical models of prostate cancer. Endocrine-Related Cancer, 20, 321-337.
167. Iacopino, F., Urbano, R., Graziani, G., Muzi, A., Navarra, P., & Sica, G. (2008). Valproic acid activity in androgen-sensitive and - insensitive human prostate cancer cells. International Journal of Oncology, 32, 1293-1303.
168. Welsbie, D. S., Xu, J., Chen, Y., Borsu, L., Scher, H. I., Rosen, N., et al. (2009). Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Research, 69, 958-966.
169. Molife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., et al. (2010). Phase II, two-stage, single-arm trial of the histone deacetylase inhibitor (HDACi) romidepsin in metastatic castration-resistant prostate cancer (CRPC). Annals of Oncology, 21, 109-113.
170. Wang, Y., Lonard, D. M., Yu, Y., Chow, D.-C., Palzkill, T. G., & O'Malley, B. W. (2011). Small molecule inhibition of the steroid receptor coactivators, SRC-3 and SRC-1. Molecular Endocrinology, 25, 2041-2053.